Candriam S.C.A. Aldeyra Therapeutics, Inc. Transaction History

Candriam S.C.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 13, 2022	SELL	$3.25 - $5.17 $455,000 - $723,800	-140,000 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$10.44 - $14.85 $1.46 Million - $2.08 Million	140,000 New	140,000 $1.59 Million

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $249M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.